

HRT is not a “one size fits all” treatment. Explanation of why various doses are prescribed to different people

Newson Health Clinic was founded in 2018 to help women receive treatment for their menopausal and perimenopausal symptoms. Many women come to our clinic because they are unable to get help on the NHS and/or because the type of HRT they are receiving is insufficient to alleviate their symptoms.

At Newson Health, our patients are central to all treatment decisions. We start our patients with the minimal effective doses of hormones, then assess scope for any changes based on clinical response and patients' views.

We follow [NICE menopause guidelines](#), adhere to the [General Medical Council's decision making and consent guidelines](#), and [NICE shared decision-making guidelines](#) [1-3].

In this document we share our background to this approach.

Background on HRT prescribing and doses

The decision as to whether to prescribe HRT, the dose of HRT given, and the duration of its use is made on an individualised basis after discussing the benefits and risks with each patient.

The optimum dose and duration of HRT treatment is decided according to the severity of a woman's symptoms, her response to treatment and how the HRT is absorbed and metabolised in her body. Every woman is different so a “one size fits all” approach to HRT is not the best for women. Medicine is both a science which uses scientific evidence and art to respond to individuals.

There are many benefits of taking HRT as it usually improves symptoms and can also improve future health by reducing future risk of important diseases including heart disease, osteoporosis, type 2 diabetes, bowel cancer, clinical depression and dementia. Many women choose to take HRT for ever and there is no maximum time for taking HRT.

The dose of hormones – oestrogen, progesterone and testosterone - can vary between women and often women find that their doses need to change (either increase or decrease) with time. For example, a woman may start on a low dose during the perimenopause and then increase as her own hormones decline with time.

Some women need higher doses of oestrogen than other women to achieve the same benefits, especially as oestrogen can often be absorbed differently through the skin.

Is there a maximum dose of hormones?

The manufacturers in the UK have set a recommended maximum dose for each HRT medication. They have done this studying a very small number of women (less than 40) for only a very short time (some studies only 4 days) and have only studied women who are menopausal and not women who are perimenopausal.

Monitoring average oestradiol (oestrogen) levels over such a short period of time can be misleading because there is substantial individual variation in oestradiol pharmacokinetics,

research has shown there can be up to 10-fold differences in oestradiol levels between women using the same dose patch or gel [4].

Some women have suboptimal oestrogen levels even when using the highest licensed dose, studies have shown between 5 and 20% of women are so-called 'poor absorbers' which means that they do not absorb the oestrogen gel well through their skin [5]. These women are likely to require higher off-label doses or a change in formulation (for example change from a patch to a gel) to achieve physiological levels of oestradiol [6].

This does not mean that higher doses are not safe though. The British National Formulary (BNF), a medical and pharmaceutical publication that contains information and advice on prescribing and pharmacology, states that doses of oestradiol should be adjusted according to response [7].

In addition, a consensus statement by the British Menopause Society states that HRT dosage, regimen and duration should be individualised, with annual evaluation of advantages and disadvantages [8].

Newsom Health's position on evidence-based medicine

Evidence based medicine is based not only on clinical trial data, but also a clinician's experience and expertise individualised to a patient's values and preferences. This approach is particularly important in menopause care and women's health because they are undervalued, underfunded and under-researched.

Newsom Health clinicians use both individual clinical expertise and the best available external evidence, and neither alone is enough. Absence of evidence does not mean proof of harm.

Off-label is not the same as unlicensed

Many medicines, including HRT, are prescribed 'off-label' – meaning it is used in a different way described in the license, for example using a medicine at a higher dose than stated in the license. There are many medicines that are prescribed off-label for example some medication for children, some medication for migraines and mental health conditions.

Note: this is not the same as 'unlicensed', which is a medicine that has no license, either in the UK or elsewhere. Oestrogen in HRT is a licensed treatment.

Newsom Health clinicians refer to Medicines and Healthcare products Regulatory Agency (MHRA) guidance on off-label or unlicensed use of medicines and best practice for patient communication [9].

Maximum doses explained

Manufacturers usually state a recommended maximum dose for a medication. However, this does not mean prescribing over that level is dangerous nor that clinicians cannot or should not do so – higher doses may be essential for an individual patient's needs.

In the case of HRT, it is well documented there is a wide variation in the efficiency of transdermal drug (oestrogen as a patch, gel or spray) delivery across individuals. Absorption can be affected by both modifiable and non-modifiable factors such as sex, age, ethnicity hydration, skin temperature, metabolism, and site of application [10-13].

Newsom Health audit data has shown that there is usually no strong correlation between dose of oestrogen prescribed and blood levels of oestrogen in the body. There are many women who use lower doses and have higher levels of oestradiol in their bodies than other women who are using higher doses.

Furthermore, recent evaluation of Newson Health clinic data looking at over a thousand women has shown that women often require variable blood concentrations of oestradiol for adequate perimenopausal and menopausal symptom control. This data is currently being written up and submitted for an academic publication.

It follows that two patients on the same dosage of oestradiol may therefore absorb quite different amounts, meaning that the patient who absorbs less will often need to be prescribed a higher dose simply to ensure her serum levels are equivalent to a patient who has better absorption. References to “high” or “low” doses cannot be made about the general population because patients will often benefit from different doses of oestradiol in the HRT they are prescribed.

Response to any hormone treatment is unique to each woman, some women responding well to a low dose of one preparation while not responding well to a high dose of another.

In practical terms, the dose of oestradiol needs to be individualised to each woman, and many women need to have their dose altered – either increased or decreased – with time.

There is no robust evidence that higher doses of oestrogen are associated with a greater risk to a patient as there have been no randomised controlled trials undertaken in this area.

How often does Newson Health prescribe above the manufacturer’s maximum dose?

Many women come to Newson Health because they are unable to access help on the NHS and/or because the prescription they are receiving is insufficient to alleviate their symptoms. About a third of women who come to Newson Health are already taking HRT but they are still experiencing symptoms and their dose and/or type of HRT needs altering.

A minority of Newson Health’s follow up patients are receiving a dose of oestradiol higher than the maximum stated dose. However these women will have already been prescribed lower doses, with inadequate results in terms of either symptom control, blood levels, or both. Newson Health does not start women who have never taken HRT before on a “high” dose.

Newson Health have developed and produced various treatment pathways which our clinicians use.

The aims of our prescribing pathways

- to standardise the treatment of women receiving higher doses of oestradiol
- maintain patients’ wellbeing and safety
- support individualised care
- adhere to the MHRA guidance about prescribing off-label
- uphold the integrity of Newson Health and its clinicians

Oestradiol blood tests

Some women using oestrogen as a patch or gel are recommended to have their oestradiol blood test undertaken. However, oestradiol blood level results need to be interpreted with caution as they can be unreliable.

The usual range is similar to the range for women who are still having periods, so the usual physiological range is 250-1000pmol/L. Women who have raised levels are usually offered a repeat test and if blood level remains elevated and there is no other underlying reason then

we usually recommend woman to reduce their dose but to increase again if their symptoms return.

However, fluctuations in oestradiol levels can be normal if the woman is perimenopausal and so levels of oestrogen can be very high as well as very low.

Women are usually advised not to apply their oestrogen gel to their arms on the morning before their blood test and to apply it to their legs on the day of the blood test if they usually apply the gel on their arms. Using gel on their arms on their day of blood test can lead to falsely raised levels [14].

In addition, there can be cross reactivity with other substances (such as biotin) so a high level may not be accurate for oestradiol.

Oestradiol results are not interpreted in isolation as the clinical situation is always taken into consideration.

Note about progesterone dose

The Newson Health treatment pathways for women who bleed while taking HRT state that dose of progesterone should be increased, regardless of the dose of HRT in addition to these women having appropriate investigations when clinically indicated. There is no good quality evidence from studies demonstrating that a higher dose of progesterone should routinely be given for women who are prescribed different doses of oestrogen and do not have any bleeding or have low oestradiol blood levels despite a higher dose.

References

1. <https://www.nice.org.uk/guidance/ng23>
2. <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/decision-making-and-consent>
3. <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/shared-decision-making>
4. Armston A, Wood P. Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis? *Ann Clin Biochem.* 2002;39(Pt 3):184-93.
5. Armston A, Wood P. Hormone replacement therapy (oestradiol-only preparations): can the laboratory recommend a concentration of plasma oestradiol to protect against osteoporosis? *Ann Clin Biochem.* 2002;39(Pt 3):184-93.
6. Jarvinen A, Backstrom A, Elfstrom C, Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. *Maturitas.* 2001;38(2):189-96.
7. <https://bnf.nice.org.uk/drugs/estradiol/>
8. British Menopause Society (2020), 'BMS & WHC's 2020 recommendations on hormone replacement therapy in menopausal women'
9. <https://www.gov.uk/drug-safety-update/off-label-or-unlicensed-use-of-medicines-prescribers-responsibilities#prescribing-in-a-patients-best-interests>
10. Tinhofer I.E., Zaussinger M., Geyer S.H., Meng S., Kamolz L.P., Tzou C.H., Weninger W.J. (2018), 'The dermal arteries in the cutaneous angiosome of the descending genicular artery', *J Anat*, 232(6) pp.979-86. doi: 10.1111/joa.12792.
11. Singh I., Morris A.P. (2011), 'Performance of transdermal therapeutic systems: effects of biological factors', *Int J Pharm Investig*, 1(1):4-9. doi: 10.4103/2230-973X.76721.
12. Liu, P., Higuchi, W.I., Ghanem, A.H., Good, W.R. (1994), 'Transport of beta-estradiol in freshly excised human skin in vitro: diffusion and metabolism in each skin layer', *Pharmaceutical Research*, 11(12), pp.1777-84. doi.org/10.1023/a:1018975602818
13. Leopold C.S, Maibach H.I, (1996), Effect of lipophilic vehicles on in vivo skin penetration

of methyl nicotinate in different races, *International Journal of Pharmaceutics*, 139, 1–2, pp.161-67, doi.org/10.1016/0378-5173(96)04562-0.

14. Vihtamäki, T., Luukkaala, T., Tuimala, R. (2004), 'Skin contamination by oestradiol gel--a remarkable source of error in plasma oestradiol measurements during percutaneous hormone replacement therapy', *Maturitas*, 48(4), pp. 347–53. [https://doi.org/10.1016/S0378-5122\(03\)00043-4](https://doi.org/10.1016/S0378-5122(03)00043-4)